FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:848-850 February 27, 2003 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hadziyannis, S. J. Related Article by Marcellin, P. PubMed Citation

Clinicians caring for patients with chronic viral hepatitis face complex challenges. The ultimate goal of therapy for chronic hepatitis is to heal hepatic inflammation and necrosis, thereby halting progression to cirrhosis and hepatocellular carcinoma. Although our understanding of the mechanisms of liver injury, fibrosis, regeneration, and repair is incomplete, it is apparent that the key to successful therapy for chronic viral hepatitis is the durable suppression of viral replication. Potential approaches using antifibrotic, cytoprotective, or proregenerative agents will remain secondary to the use of drugs that directly inhibit viral replication. Effective long-term suppression of viral replication requires medications that are . . . [Full Text of this Article]

Source Information

From the Department of Internal Medicine, University of Nebraska Medical Center, Omaha.

This article has been cited by other articles:

• Yeon, J E, Yoo, W, Hong, S P, Chang, Y J, Yu, S K, Kim, J H, Seo, Y S, Chung, H J, Moon, M S, Kim, S-O, Byun, K S, Lee, C H (2006). Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55: 1488-1495 [Abstract] [Full Text]  
• (2003). Adefovir: New Antiviral Agent for Treatment of Chronic Hepatitis B. JWatch Infect. Diseases 2003: 1-1 [Full Text]